Powder: -20°C for 3 years | In solvent: -80°C for 1 year
LW6 (HIF-1α inhibitor) is a novel HIF-1 inhibitor.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
2 mg | In stock | $ 39.00 | |
5 mg | In stock | $ 63.00 | |
10 mg | In stock | $ 91.00 | |
25 mg | In stock | $ 193.00 | |
50 mg | In stock | $ 313.00 | |
100 mg | In stock | $ 472.00 | |
500 mg | In stock | $ 987.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 63.00 |
Description | LW6 (HIF-1α inhibitor) is a novel HIF-1 inhibitor. |
Targets&IC50 | MDH2:6.3 μM, HIF:4.4 μM |
In vitro | LW6 decreases the expression of HIF-1α protein without affecting HIF-1β expression. LW6 affects the stability of the HIF-1α protein. LW6 promotes the degradation of wild type HIF-1α while not of a DM-HIF-1α with modifications of P402A and P564A, at hydroxylation sites in the oxygen-dependent degradation domain. LW6 induces the expression of von Hippel-Lindau (VHL), which interacts with prolyl-hydroxylated HIF-1α for proteasomal degradation. The knockdown of VHL does not abolish HIF-1α protein accumulation in the presence of LW6 which indicates that LW6 degraded HIF-1α via regulation of VHL expression[2]. In MDCKII-BCRP cells overexpressing BCRP, LW6 enhances significantly the cellular accumulation of mitoxantrone, a BCRP substrate. LW6 also down-regulates BCRP expression at concentrations of 0.1-10 μM[3]. LW6 inhibits the expression of HIF 1α induced by hypoxia in A549 cells at 20 mM, independently of the von Hippel Lindau protein. LW6 induces hypoxia selective apoptosis together with a reduction in the mitochondrial membrane potential[4]. |
In vivo | LW6 exhibits potent anti-tumor activity in vivo, leading to reduced HIF-1α expression as observed through immunohistochemical staining of frozen tissues in mice with xenografts derived from human colon cancer HCT116 cells[2]. |
Cell Research | Inhibition of HIF-1a is assayed by a reporter assay using dualluciferase reporter assay system. HCT116 cells in 75-90% confluence are transiently co-transfected with pGL3-HRE-luciferase plasmid containing six copies of HREs from human VEGF genes and pRLSV40 encoding firefly renilla luciferase and incubated for 24 h. Cells are treated with LW6 or 17-AAG for 16 h before report assay. Luciferase activity is integrated over a 10 second period and measured using a luminometer[2]. |
Synonyms | HIF-1α inhibitor, CAY10585, LW8 |
Molecular Weight | 435.51 |
Formula | C26H29NO5 |
CAS No. | 934593-90-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 50 mg/mL (114.81 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
LW6 934593-90-5 Angiogenesis Apoptosis Chromatin/Epigenetic Metabolism Dehydrogenase HIF/HIF Prolyl-Hydroxylase HIF LW 6 HIF-1α inhibitor Hypoxia-inducible factors inhibit CAY10585 HIF-PH CAY-10585 LW-6 HIFs LW 8 Inhibitor LW-8 HIF-1alpha inhibitor LW8 HIF-1a inhibitor CAY 10585 inhibitor